Table 1. Overview of RAS binding peptides.

Name (PDB ID)	RAS specificity	KD (nM)	Site on RAS	Properties	Ref.
Linear
RBDv1, RBDv12	GTP-RAS	3.35 2.52	P4	14 aa, inhibits RAS signalling, reduces cancer cell growth	[69]
SAH-SOS1	GDP-/GTP-RAS	106–175	near P4	16 aa, blocks nucleotide exchange, reduces cancer cell growth	[70]
225-11 (5WPL)	GTP-RAS	3.3	P4	32 aa, blocks effector interaction	[71]
R11.1.6 (5UFQ)	RAS-G12D	4	switch II	61 aa, blocks effector interaction, inhibits RAS signalling	[72]
Cyclic
Cyclorasin 9A5	GTP-RAS	440	near P4	11 aa, blocks effector interaction, inhibits RAS signalling	[73]
Cyclorasin B4-27	GTP-RAS	21	near P4	16 aa, blocks effector interaction (cellular BRET-assay)	[74]
KRpep-2d (5XCO)	KRAS-G12D	51	P2	19 aa, inhibits RAS signalling, reduces cancer cell growth	[75–77]
KS-58	KRAS-G12D	22	P2	11 aa, inhibits RAS signalling, reduces cancer cell growth in vivo	[78,79]
KD2 (6WGN)	GTP-KRAS-G12D	none	near P2	15 aa, blocks effector interaction	[80]

Peptide and peptidomimetic RAS binders and their properties. The PDB ID is given if the complex with RAS was determined.